extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
1e8be39f7f
commit
f325825ed0
6 changed files with 64 additions and 1 deletions
|
|
@ -41,6 +41,12 @@ MA plans' near-universal prior authorization creates administrative friction tha
|
|||
|
||||
MASH/NASH is projected to become the leading cause of liver transplantation. GLP-1s now demonstrate efficacy across three major organ systems (cardiovascular, renal, hepatic), which strengthens the multi-indication economic case for chronic use. The 62.9% MASH resolution rate suggests GLP-1s could prevent progression to late-stage liver disease and transplantation, though the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades and falls outside typical budget scoring windows.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Peer-reviewed Medicare modeling shows net savings of $715M over 10 years when a single payer captures multi-indication benefits across T2D, obesity, and MASH. The inflationary impact appears to be a function of payment fragmentation, not inherent drug economics—Medicare as a unified risk-bearer shows positive ROI while fragmented commercial markets may not.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -42,6 +42,12 @@ SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semagluti
|
|||
|
||||
Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo. Meta-analysis confirms GLP-1 RAs significantly increase histologic resolution of MASH, decrease liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation. Some hepatoprotective benefits appear at least partly independent of weight loss, suggesting direct liver effects beyond metabolic improvement. This adds hepatic protection as a third major organ system (alongside cardiovascular and renal) where GLP-1s demonstrate protective effects.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare modeling quantifies the multi-organ benefit: 38,950 CV events avoided, $892M in T2D savings, $28M in MASH savings, and $2,074 per subject in CKD cost avoidance over 10 years. The cardiovascular benefit alone ($1,512/subject in avoided event costs) represents substantial value beyond the primary metabolic indication.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
- FDA indication expansion to T2D patients with CKD (2024)
|
||||
- Dialysis cost benchmark: $90K+/year per patient
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare modeling estimates $2,074 per subject in CKD-related cost savings, supporting the claim that kidney protection creates substantial economic value. This is the second-largest savings category after T2D complications ($14,431/subject).
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ The composition of spending shifts dramatically: less on chronic disease managem
|
|||
|
||||
(extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
The Medicare semaglutide model provides a boundary condition: when a single payer captures multi-indication prevention benefits, the cost curve can bend down rather than up. The $715M net savings suggests that payment structure—not just clinical capability—determines whether new therapeutics are inflationary. Fragmented commercial insurance may still experience the inflationary dynamic while integrated payers see deflation.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,14 @@ Key findings:
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
|
||||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Semaglutide Medicare modeling projects 38,950 cardiovascular events avoided over 10 years
|
||||
- Semaglutide Medicare modeling projects 6,180 deaths avoided over 10 years
|
||||
- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime treatment costs: $47,353
|
||||
- T2D-related savings: $14,431 per subject; CKD savings: $2,074 per subject; CV event savings: $1,512 per subject
|
||||
- T2D indication saves Medicare ~$892M over 10 years
|
||||
- Obesity indication costs Medicare ~$205M over 10 years
|
||||
- MASH indication saves Medicare ~$28M over 10 years
|
||||
|
|
|
|||
Loading…
Reference in a new issue